FDA Convenes Landmark Public Hearing on Psychedelic Therapeutics as Agency Finalizes Regulatory Framework
核心洞察
The FDA held a public hearing on the future therapeutic use of psychedelics, drawing more than 1,800 registered attendees and roughly 80 scheduled speakers.
The hearing followed the agency's July 2026 finalized guidance on psychedelic clinical investigations and an April executive order aimed at accelerating access.
Speakers clashed over provider credentialing, patient safety, rural access, and the need for standardized adverse event and outcome data.
The U.S. Food and Drug Administration (搜索) convened a public hearing on the potential future therapeutic use of psychedelic drugs, drawing more than 1,800 registered attendees and roughly 80 scheduled speakers who delivered two-minute comments at the agency's White Oak campus in Silver Spring, Maryland. The hearing, held in collaboration with the National Institute on Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (搜索) (SAMHSA), the Veterans Health Administration (VHA), and the Advanced Research Projects Agency for Health (搜索) (ARPA-H), focused on four topic areas: provider training and credentialing, patient safety, access, and data standardization.
"Today's hearing is part of a whole of government effort to better understand the opportunities, challenges, and public health considerations associated with this evolving area of psychedelic drug treatment," said Marta Sokolowska, Deputy Center Director for Substance Use and Behavioral Health at FDA's Center for Drug Evaluation and Research, in opening remarks. "Most importantly, we are here today to listen." Sokolowska noted that FDA has taken "a number of steps to advance psychedelic drug development," including publishing guidance for researchers, partnering with other agencies, and taking regulatory actions intended to support an executive order signed earlier this year directing the acceleration of innovative research models and appropriate drug approvals.
Dayle Cristinzio, FDA's Director of Public Engagement, said the hearing was "not intended for the promotion of any specific drug or commercial product" and was instead focused on gathering perspectives "that may help inform continued work in this area for FDA and our federal partners." She explained that speakers were selected randomly from more than 200 requests to speak, a pool reviewed for administrative completeness and to limit duplicative perspectives. "Selection was not based on the anticipated substance or viewpoint of a requester's comments," Cristinzio said, adding that selection to speak "does not constitute endorsement by FDA or participating federal partners of any speaker, organization, viewpoint, product, position, or regulatory outcome."
Newly installed CDER Director Michael Davis attended the afternoon session. Davis previously served as Chief Medical Officer at the Usona Institute, a non-profit research organization studying psilocybin in mental health treatments, and ahead of the hearing he published a commentary with FDA colleagues in the New England Journal of Medicine outlining the agency's new framework for psychedelics.
A Regulatory Framework Taking Shape
The hearing came at a pivotal regulatory moment. In April 2026, FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression (搜索), psilocybin for major depressive disorder (搜索), and methylone (MDMC) for PTSD. The agency also allowed an early-phase trial of noribogaine chloride (搜索) for alcohol use disorder (搜索) to proceed under an Investigational New Drug application. In July 2026, FDA finalized its guidance, "Psychedelic Drugs: Considerations for Clinical Investigations," which supersedes a draft issued June 26, 2023, and covers classic 5-HT2A (搜索) agonists such as psilocybin and LSD alongside entactogens such as MDMA. The agency also published a commentary in the New England Journal of Medicine outlining its new regulatory framework, which appeared in the journal's September 10, 2026 issue.
FDA also signed a memorandum of understanding with the Department of Veterans Affairs to collaborate on research and development of psychedelic medicines for serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies, and lawmakers have since filed a bill that would require the Department of Defense to evaluate how psilocybin research could help members of the military, along with a separate bipartisan measure to codify the executive order into law.
Credentialing: Competency Over Credentials
The most contested topic was who should be permitted in the treatment room and what qualifications they need. Rajan Dunne, a psychiatrist at Sheppard Pratt who has cared for roughly 200 participants across more than 10 psychedelic trials, argued that psychiatrists should be required to lead psychedelic treatment. "I think we need to step back and ask: access to what? Because access to psychedelics is not the same thing as access to good care," Dunne said, warning that commercial pressures could sideline psychiatric expertise behind a veneer of clinical legitimacy. By contrast, a Columbia University professor argued against novel licensing layers, contending that psychedelic treatment should remain within mainstream behavioral health scope of practice to prevent patients from being diverted to less regulated settings.
Laurel Kilgour, an attorney with the non-profit Psychedelic Bar Association, warned that overly zealous regulation might push people underground and called for regulators to revisit requirements as real-world data accumulates. "This is a learning process for all of us that should be revisited along the way," she said.
Michaela Vogt of Colorado's NeuroAlchemy healing center framed the therapeutic components as inseparable from the molecule. "Healing is rarely the product of a molecule alone," Vogt said. "Preparation gives it direction. The therapeutic relationship gives it safety. Integration gives it durability."
Shasta Winn, founder of the Oregon-based psilocybin facilitator training program Myco-Method, cited a JAMA Network Open multi-site study of 346 Oregon patients in which four experienced serious adverse events; only one was identified during the session, with the other three surfacing weeks later through follow-up — an argument for longitudinal safety monitoring rather than session oversight alone. Multiple speakers called for competency-based assessment rather than hourly training requirements, with a simulation platform founder noting that hours are easy to satisfy and hard to verify, while demonstrated competency can be audited. Representatives from nursing, pharmacy, and occupational medicine each argued their professions were underrepresented in current guidance, and the American Pharmacists Association formally requested that pharmacists be recognized as essential members of the psychedelic care team, citing existing infrastructure for controlled substance storage, inventory, and compliance.
Australia's experience drew direct comparison. A representative of a publicly traded Australian company reported conducting more than 500 dosing sessions since October 2023 under that country's authorized prescriber scheme, with no severe adverse reactions and with coverage from Australia's largest private insurer and its veterans affairs department. The company treats patients excluded from clinical trials, including those with elevated blood pressure and personality disorders — a population panelists noted represents the real-world caseload more accurately than trial enrollees.
Access: Geography, Cost, and the Insurance Gap
Access concerns dominated the afternoon session. Jon Dalton of the Nevada Coalition for Psychedelic Medicines noted that nearly 87% of Nevadans live in a federally designated mental health professional shortage area, and that the FDA's July guidance recommendation — that a physician be reachable within 15 minutes when a non-physician serves as lead monitor — would effectively disqualify every clinic in rural and frontier Nevada. "That requirement could exclude otherwise qualified clinics from providing care," Dalton said, urging the agency to allow product-specific emergency protocols combining on-site personnel, remote physician consultation, and EMS activation.
A founder of one of the country's largest brain medicine networks, operating TMS and ketamine across 27 clinics in seven states, offered a cautionary data point: esketamine was approved in 2019, but sales were so small for the first two years that they were not separately reported, and it took five years to reach scale. The speaker made three requests: write labels with payers in mind so that undefined terms cannot become denial criteria; standardize adverse event capture and outcome measures before launch; and work with CMS on permanent CPT codes that reflect the full cost of a trained team in a room for a full day.
A documentary filmmaker who spent eight years filming psychedelic therapy training reported that the clinics most likely to close were not shut down by adverse events but because patients could not pay, citing a low-income clinic in Oregon and a ketamine clinic in Lubbock, Texas that failed due to reimbursement gaps, leaving patients mid-treatment with no follow-up.
Speakers also raised women's health as an underserved area. One advocacy founder cited National Academies data showing that from 2013 to 2023, just 8.8% of NIH research grant funding went to women's health research. A clinical pharmacist noted that menstrual cycle phase, pregnancy, postpartum status, perimenopause, and menopause all alter neurobiology and pharmacology, yet these variables are routinely excluded from psychedelic trials or treated as confounders. Other commenters advocated for populations they worried could be left behind, including cancer survivors, patients with terminal diagnoses, those with chronic pain, and individuals with cochlear implants.
Not all speakers supported accelerated access. A former Office of National Drug Control Policy advisor cited rising hallucinogen-related emergency department visits, a Canadian study linking hallucinogen ER visits to 3.5 times greater likelihood of developing schizophrenia (搜索), and an 8-fold increase in psilocybin poison control cases among children under 12 over five years. He urged FDA to require full scientific approval before expanding access and warned against allowing advocacy pressure to substitute for rigorous trial evidence. Susan Taymor Sagy of the non-profit Coalition for Psychedelic Safety and Education warned that "FDA approval will carry enormous cultural weight," and that as psychedelics become more normalized, use outside regulated clinical settings may increase without the screening, supervision, and safeguards required in an FDA-approved treatment.
Data Standardization: Build the Infrastructure Now
Multiple speakers argued that the window to establish common data elements is closing, and that waiting until registries are built will make meaningful comparison impossible. "Design connection from the start, so real-world evidence can improve safety, workforce standards, and access," said Shanetha Lewis of Maryland's Task Force On The Responsible Use of Natural Psychedelics.
Edward Jacobs, a Johns Hopkins postdoctoral researcher, presented a meta-analysis from his lab published in JAMA Psychiatry finding that roughly 4% of psychedelic trial participants with pre-existing psychiatric conditions encountered serious adverse events even with intensive oversight and restrictive screening. "Real-world risk is more likely to be underestimated than overestimated," Jacobs said. "It's better to start with stronger protections and adjust them as the evidence accumulates, than to start with weaker protections and tighten them after harm." He recommended anchoring initial post-approval safeguards closely to trial conditions, with pre-specified review points and defined evidentiary thresholds for relaxing or tightening requirements.
A regulatory consultant specializing in ibogaine warned that no validated cardiac prediction model currently exists for ibogaine despite documented QTc prolongation and ventricular arrhythmia at therapeutic doses. She called for a minimum common data element set — including metabolizer status, time-matched ECG, drug dose, and indication — to be published before registry infrastructure is built, arguing that a registry without common data elements produces volume, not evidence.
Alia Lilienstein of UC Berkeley's Center for the Science of Psychedelics called for a standardized glossary of psychedelic adverse events, noting that FDA guidance requires investigators to document all central nervous system effects as adverse events regardless of valence. Without common definitions, she argued, trial safety data reflects each team's interpretation rather than the drug's actual risk profile. Her team is developing a glossary in collaboration with UCSF and invited FDA to participate.
A Puerto Rico researcher flagged a structural gap: the National Survey on Drug Use and Health, the primary source for national psilocybin prevalence estimates, has no territorial sample frame, meaning approximately 3.2 million American citizens are excluded from the baseline data underpinning regulatory decisions. He called for territory inclusion as a foundational design requirement in any federal registry.
What the Finalized Guidance Requires of Sponsors
The July 2026 guidance carries operational requirements that extend well beyond documentation. It requires sponsors to address "set and setting" in trial protocols — the physical environment, psychological support structure, and therapist training standards must all be specified and justified under an IND application. During treatment sessions, two trained monitors are required, with the lead monitor possessing relevant clinical training and experience; dosing sessions are expected to last multiple hours, during which monitors must remain with the subject.
The guidance also directs sponsors to describe how they plan to assess the degree of functional unblinding and to address the potential bias it introduces in their statistical analysis plans, acknowledging that the profound subjective effects of psychedelic drugs can unblind participants, investigators, and study staff. It notes that active placebos, such as low-dose versions of the investigational psychedelic or other psychoactive substances, may help maintain blinding but introduce additional considerations regarding safety and interpretation of results. Informed consent documents must clearly describe that subjects may experience changes in perception, cognition, and judgment persisting for many hours, as well as increased vulnerability and suggestibility during the treatment session.
The guidance does not resolve the DEA registration process that sponsors running Schedule I psychedelic trials must navigate under 21 CFR Part 1301, a process involving security requirements, vault-level storage standards, and chain-of-custody documentation that operates on a timeline independent of FDA review. Usona Institute's Breakthrough Therapy designation for psilocybin in major depressive disorder (搜索), granted in 2019, has not translated into a filed NDA seven years later, partly because of the regulatory and logistical complexity of Schedule I research registration. COMPASS Pathways, whose COMP360 psilocybin formulation received Breakthrough Therapy designation for treatment-resistant depression (搜索) in 2018, reported 29.1% remission at week 3 in the 25mg arm of its Phase 2b trial, double the rate of lower-dose arms.
The MAPP2 MDMA-assisted therapy trial exposed the blinding problem directly: 71.2% of participants in the MDMA-assisted therapy arm no longer met DSM-5 criteria for PTSD at end of study, versus 47.6% in the placebo-with-therapy group. MAPP1 enrolled 90 patients across multiple sites, while MAPP2 enrolled at least 100 participants across 13 U.S. and Israeli sites, completing enrollment May 9, 2022.
Real-World Harm and the Treatment Gap
A recurring theme throughout the hearing was that the treatment gap is already generating real-world harm. Multiple speakers, including veterans and a combat-wounded nurse practitioner, described traveling outside the United States, to Mexico and other countries, to access ibogaine and ayahuasca because domestic options did not exist. One Iraq War veteran described years of underground practice to keep fellow veterans from dying by suicide. A retired Green Beret said ketamine therapy was "like a reset button" after half a dozen psychiatric medications failed him, and described nearly needing crisis intervention himself before finding treatment.
The FDA's public docket for the hearing remains open at regulations.gov (Docket No. FDA-2026-N-7542) through October 5, 2026. The agency indicated that written comments, alongside testimony from the hearing, will inform continued federal coordination across FDA, VA, SAMHSA, NIDA, and ARPA-H.